Contents & References of Investigating the anti-inflammatory effects of newly synthesized N-aryl phthalamide derivatives
List:
Persian summary.. 1
Chapter one: General
1- 1. Necessity and importance of the topic.. 3
1- 2. Purpose.. 3
Chapter two: review of other texts and studies in this field
Part one: Review Texts 2-1-1. Introduction.. 5
2-1-2. History.. 7
2-1-3. Inflammation.. 7
2-1-3-1. Symptoms of inflammation..9
2-1-3-2. mediators of inflammation..9
2-1-3-3. Inflammatory response..9
2-1-4. Eicosanoids..11
2-1-4-1. Definition.. 11
2-1-4-2. Structure and biosynthesis..11
2-1-5. Cyclooxygenase pathway..14
2-1-5-1. Prostaglandins..18
2-1-5-1-1. History.. 18
2-1-5-1-2. Building.. 18
2-1-5-2. Biological effects of prostanoids. 19
2-1-5-2-1. The role of prostanoids in the process of pain and inflammation. 21 2-1-6-3. Cyclooxygenase enzyme and its isoforms. 21 2-1-5-3-1. Biochemical structure of cyclooxygenase enzyme isoforms. 22 2-1-5-3-2. Three-dimensional structure of cyclooxygenase enzyme. 23
2-1-5-3-3. The active site of cyclooxygenase. 25
2-1-5-3-4. Comparison of the active site of cyclooxygenase cox-1 and cox-2. 27
2-1-5-3-5. Comparison of cox-1 and cox-2 in relation to cyclooxygenase inhibitors. 29
2-1-5-3-6. Investigating the crystal structure of cox-1 enzyme complex and inhibitor. 30
2-1-5-3-7. Investigation of the crystal structure of cox-2-inhibiting enzyme complex. 31
2-1-6. Cyclooxygenase inhibitors. 33
2-1-6-1. Classical inhibitors (non-selective). 34
2-1-6-1-1. Structural classification of cyclooxygenase enzyme non-selective inhibitors. 34
2-1-6-1-1-1. Salicylates.. 38
2-1-6-1-1-2. Arylalkanoic acids. 39
2-1-6-1-1-3. N-aryl anthranilic acids (phenamates). 40
2-1-6-1-1-4. Enoic acids (oxicams). 41
2-6-1-2. Cyclooxygenase inhibition mechanism by non-selective inhibitors. 42 2-1-6-1-3. Therapeutic applications of non-selective cyclooxygenase inhibitors. 43 2-1-6-1-3-1. Anti-inflammatory activity of non-steroidal anti-inflammatory drugs. 43
2-1-6-1-3-2. Antipyretic effects of non-steroidal anti-inflammatory drugs. 44
2-1-6-1-3. Side effects of non-selective cyclooxygenase enzyme inhibitors. 44
2-1-6-1-4-1. Gastrointestinal complications. 45
2-1-6-1-4-2. Skin complications: 47
2-1-6-1-4-3. Kidney complications: 47
2-1-6-1-4-4. Liver complications: 48
2-1-6-1-4-5. Effects of non-steroidal anti-inflammatory drugs on platelets. 48
2-1-6-1-4-6. Photosensitivity reaction: 48
2-1-6-2. Selective COX2 inhibitors. 48
2-1-6-2-1. Structural classification of cox-2 selective inhibitors. 49
2-1-7. Lipoxygenase pathway.. 50
2-1-8-1. Leukotrienes.. 50
2-1-7-1-1. Biosynthesis.. 51
2-1-7-1-2. Biological effects of leukotrienes. 54
2-1-7-1-3. The effects of leukotrienes in the inflammation process. 55
2-1-7-2. Leukotriene inhibitors: 56
2-1-7-2-1. Antioxidants: 56 2-1-7-2-2. Iron chelators: 57
2-1-7-2-3. Competitive inhibitors: 58
. 59 FLAP. Inhibitors of 2-1-7-2-4
2-1-7-2-5. Leukotriene receptor antagonist: 60
2-1-8. Non-enzymatic pathways. 61
2-1-8-1. Isoprostane pathway.. 61
2-1-8-2. Malondialdehyde.. 64
2-1-8-4.3 Hydroxynonenal 4-Hydroxynonenal. 65
2-1-8-4. The role of superoxide and nitric oxide in inflammatory processes. 66
Part Two: Studies by others in this field
2-2-1. Review the studies of others in this field. 70
2-2-2. Simultaneous COX/LOX inhibitors: 71
2-2-2-1. Modified NSAIDs: 71
2-2-2-2. Derivatives of N-aryl phthalimides: 71 Chapter 3: Materials and methods 3-3. Pharmacological steps. 76 3-3-1. Animals. 76 3-3-2. Preparation of samples for pharmacological tests. 76
3-3-3. Anti-inflammatory effects.. 77
3-3-5. Statistical analysis of data. 78
Chapter four: results
Chapter five: discussion and conclusion
Discussion and conclusion. 94
English abstract. 99 references.
None.
Source:
Fiorucci S, Meli R, Bucci M. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 2001; 62 (11): p. 1433-1438
2) Garavito R.M. The cyclooxygenase-2 structure: new drugs for an old target? Nat. Struct. Biol. 1996;3 (11):p.897-901
3) Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann. Clin. Lab. Sci. 1998; 28 (2): p. 67-81
4) Hallas J, [et al]. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk groups by excess risk estimates. Scand J Gastroenterol. 1995; 30: p.438-444
5) Warner TD, Mitchell J.A. Cyclooxygenase-3: Filling in the gaps towards a COX continuum. Proc. Natl. Acad. Sci. 2002; 99:p.13371-13373
6) Pairet M, Ryn JV. COX-2 inhibitors. In: Milestones in Drug Therapy. First edition. 2004. p. 1-14
7) Dannhardt G, Keifer W. Cyclooxygenase inhibitors: current status and future prospects. Eur. J. Med. Chem. 2001; 36:p.109-126
8) Gilory DW, Tomlinson A, Willoughby DA. Cyclooxygenase may contribute to the resolution of inflammation. Eur. J. pharmacol. 1998; 355:p.211-217
9) Scott G. Stewart, Marta E. Polomska, anti inflammatory a new analog thalidomide. 2002; 28:p.2375-2382
10) Foegh ML, Ramwell PW. The eicosanoids: prostaglandins, thromboxanes, leukotrienes, and related compounds. Frust DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics and drugs used in gout. In: Katzung, Basic & Clinical Pharmacology. New York: McGraw-Hill; 2001. pp. 311-325, 596-623
11) Gelott F, Laufer S. Anti-inflammatory drugs: New multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 2001;43:429-436
12) Funk CD. Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology. Science. 2001; 294 (5548):p.1871-1875
13) Nies AS, Gresser M.J. Cyclooxygenase-2 inhibitors. Adv. Pro. Chem. 2001;56, p.115-141
14) Borne RF. Nonsteroidal anti-inflammatory agents. In: Williams DA. LemkeTL, Foye's Principal of Medicinal Chemistry. Philadelphia: Lippincott Williams & Wilkins; 2002.p. 751-793
15) Roberts LJ, MorrowJ D. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman, LG. Limbird, LE. Goodman Gilman, A. eds. Goodman & Gilman's Pharmacological Basis Of Therapeutics. New York: McGraw-Hill; 2001. p. 687-731
16) Dannhardt G, LauferS. Structural approaches to explain the selectivity of COX-2 inhibitors.Curr.Med.Chem.2000;7:p.1101-1112
17) Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971; 231: 232-235
18) Fu JY, [et al]. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 1990; 265: p. 16737-16740
19) Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclooxygenase-2 transcript isoforms by dexamethasone: evidence posttranslational regulation. Biochem. J. 1996;318:p. 325-331
20) Griag CR, Stitzel RE. Modern Pharmacology. 3rd ed. London: Little and Brown company, Boston; 1990. PP. 509,517,521-522
21) Bowman WC, Rand MJ. Text book of pharmacology. 2nd ed. Oxford: Blackwell Scientific publication; 1980. PP. 5-6, 10-21
22) Rang HD, Dale MM. Pharmacology. Edinburg: Churchill living stone; 1987.pp.61-64, 451-453, 556-557, 588
23) Sanderson JB. A system of surgery. 2 rd ed. Longmans: Green and co; 1871.p.121
24) Spector WG, Willoughby DA. The inflammatory response. Bacteriological reviews. 1963; 27: p.